Identification of the first succinate receptor agonists

Identification of the first succinate receptor agonists

 

The succinate receptor (formerly GPR91 or SUCNR1) is expressed in a variety of tissues, including blood cells, adipose tissue, the liver, retina, and kidney. Although its function remains to be established in most tissues, it has recently emerged as novel mediator in local stress situations, including in immune responses and inflammation, retinal angiogenesis and regulation of renin release.

Notwithstanding its implication in multiple (patho)physiological processes, the succinate receptor belongs to the category of attractive drug target whom the function has remained ill- defined due to unavailability of pharmacological tools.

Recently, researchers from the University of Liège (ULg) have discovered the first family of synthetic agonists, characterized for the best compound (namely cis-epoxysuccinic acid or cESA) with a 10 times higher potency compared to the natural ligand succinic acid. These tools led to the definition of a pharmacophore for agonistic activity on succinate receptors and a better understanding of its binding site. These highly potent and efficacious succinate receptor agonists have no activity on the mitochondrial SDH and can be used to specifically assess the impact of succinate receptor activation without interfering with the citric acid cycle.

The ULg’s researchers expect that the emergence of a properly characterized tool will open new possibilities for the characterization of succinate receptors and will pave the way to the development of highly selective and potent antagonists. Molecules with various pharmacological profiles are an absolute prerequisite to develop drug candidates and to validate the Succinate Receptor as an exploitable drug target in diseases with high level of unmet medical needs such as hypertension, retinal angiogenesis, inflammation and complications of diabetes mellitus or metabolic disease.

The results have been published in the British Journal of Pharmacology.

Related articles

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials

A new gene responsible for juvenile myoclonic epilepsy?

In collaboration with a team at the University of California at Los Angeles (UCLA), researchers from GIGA-Neurosciences have discovered a new gene responsible for a seizure syndrome called juvenile myoclonic epilepsy (JME). This discovery was made as part of an international consortium that studies genetic abnormalities responsible for epileptic diseases. It is being published this week in

Read more
A new gene responsible for juvenile myoclonic epilepsy?

New technologies available at the GIGA Imaging platform

The LIGHTSHEET MICROSCOPY can deliver optical sections, 3D reconstructions and timelapse movies of whole sample volumes at subcellular resolutions. The fast scan speeds and low phototoxicity of the lightsheet allow to record the development of fluorescent transgenic animals over long time periods, such as zebrafish embryos. Alternatively 3D reconstructions of fixed whole organs or whole embryos,

Read more
New technologies available at the GIGA Imaging platform

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.


We track anonymized user information to improve our website.
  • _ga 2 year
  • _gid 24 hours
  • _gat 1 minute
  • AMP_TOKEN 30 seconds to 1 year
  • _gac_ 90 days

Decline all Services
Accept all Services